Glioblastoma, which kills roughly Americans each year, remains challenging to treat. The emerging biopharmaceutical company Global Cancer Technology (GCT; San Diego) is developing a novel x-ray activated modality for drug delivery to treat glioblastoma. GCT has a licensing agreement with the University of California, San Diego (UCSD) for a drug delivery platform that unites a […]
Oncology
Orum Therapeutics raises $84M for targeted protein degrader payloads
Orum Therapeutics announced today that it closed an $84 million Series B financing for its targeted protein degraders for treating cancer. Boston-based Orum’s funding round includes a previously announced $30 million financing, plus another $54 million in new funds led by IMM Investment and joined by new investors KDB Investment and Atinum, among others. Existing […]
The potential to improve therapeutic outcomes with microfluidics
Traditional methods for drug encapsulation are limited in their ability to fabricate consistently sized, monodisperse liposomal formulations. As a result, they can negatively influence the efficacy of therapeutic drug delivery. More efficient manufacturing methods and microfluidic technologies provide an alternative, high throughput and cost-effective approach to producing nanotherapeutics. Researchers at the University of Manchester are […]
Cardinal Health wins new FDA approval for Lymphoseek
Cardinal Health (NYSE:CAH) announced today that the FDA approved its Lymphoseek injection for pediatric use. Dublin, Ohio-based Cardinal Health touts Lymphoseek — acquired from Navidea Biopharmaceuticals (NYSE:NAVB) in November 2016 — as the first and only radiopharmaceutical agent specifically designed for targeted lymphatic mapping and guiding sentinel lymph node biopsies (SLNB). The new indication will expand […]
Interius BioTherapeutics raises $76M Series A
Interius BioTherapeutics announced today that it raised $76 million in an oversubscribed Series A financing round. Philadelphia-based Interius develops treatments for hematologic malignancies. The company’s novel gene delivery platform generates chimeric antigen receptor (CAR) T cells directly in vivo to bypass the need for ex vivo cell manipulations and the potentially toxic pre-conditioning chemotherapy required […]
FDA accepts IND application for Samus Therapeutics’ oral glioma drug
Samus Therapeutics announced today that the FDA cleared its investigational new drug (IND) application for its glioma treatment. Boston-based Samus Therapeutics develops the PU-AD (icapamespib) orally administered small molecule drug for the treatment of recurrent malignant glioma, according to a news release. Under the IND, Samus will move forward with its Phase 1b study to […]
Oncopeptides completes enrollment in Phase 2 multiple myeloma study
Oncopeptides announced today that it completed patient enrollment for its Phase 2 Port study of its multiple myeloma treatment. Waltham, Mass.-based Oncopeptides’ Port study is an open-label, randomized, crossover study comparing the safety, tolerability and efficacy of peripheral or central intravenous administration of Pepaxto (melphalan flufenamide) in combination with dexamethasone to treat relapsed refractory multiple […]
D&D Pharmatech to collaborate with Yale on brain cancer therapies
D&D Pharmatec announced today that it is collaborating with Yale to optimize two approaches to treating brain cancer and other disorders. The sponsored research agreement is slated to work with two novel approaches that allow immune system cells and drug molecules to bypass the blood-brain barrier (BBB) when treating brain cancer, among other diseases, according […]
Amgen completes $1.9B acquisition of Five Prime Therapeutics
Amgen (NSDQ:AMGN) announced today that it successfully completed its $1.9 billion acquisition of Five Prime Therapeutics (NSDQ:FPRX). Thousand Oaks, Calif.-based Amgen has officially acquired South San Francisco-based Five Prime for $38 per share in cash, reaching an equity value of approximately $1.9 billion. The acquisition was initially announced on March 4, 2021. As of the […]
Oncopeptides seeks EU marketing authorization for multiple myeloma treatment
Oncopeptides announced today that it submitted an application for European marketing authorization of its melflufen therapeutic. Conditional marketing authorization from the European Medicines Agency (EMA) is the aim for the company after its pivotal phase 2 Horizon study provided positive outcomes with melflufen (melphalan flufenamide) in treating relapsed refractory multiple myeloma, according to a news […]
